ASH 2023 | Key trials in multiple myeloma presented at ASH 2023: take home messages
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy, provides an overview of the key clinical trials in the field of multiple myeloma (MM) which were presented at the ASH 2023 Annual Meeting. In the front-line setting, there is potential for a new standard of care based on data from the PERSEUS (NCT03710603) and IsKia (NCT04483739) trials. In the relapsed/refractory (R/R) setting, there is a growing body of data on novel combination therapies and on the sequencing of agents. Dr Cerchione also discusses the need for integrating measurable residual disease (MRD)-negativity as an endpoint in patients with multiple myeloma in clinical practice. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Menarini, Amgen, Takeda, Stemline Therapeutics, Servier, BeiGene, AbbVie, Pfizer, Sanofi
Honoraria: Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Menarini, Amgen, Takeda, Stemline Therapeutics, Servier, Sanofi Aventis, BeiGene, AbbVie, Pfizer
Speakers Bureau: Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Menarini, Amgen, Takeda, Stemline Therapeutics, Servier, Sanofi Aventis, BeiGene, AbbVie, Pfizer
